新型冠状病毒感染预防药物研究进展  

Research progress of prophylaxis drugs for corona virus disease 2019

作　　者：李奇隆 钟武 朱贺 樊士勇 LI Qi-long;ZHONG Wu;ZHU He;FAN Shi-yong(Institute of Pharmacology&Toxicology of the Academy of Military Medical Sciences,National Engineering and Technology Center of Emergency Prevention and Control Drugs,Beijing 100850,China;the Third Clinical Medical College,Nanjing University of Chinese Medicine,Nanjing 210028,China)

机构地区：[1]军事科学院军事医学研究院毒物药物研究所国家应急防控药物工程技术研究中心,北京100850 [2]南京中医药大学第三临床医学院,南京210028

出　　处：《临床药物治疗杂志》2023年第3期1-6,共6页Clinical Medication Journal

基　　金：国家重大新药创制科技重大专项(2018ZX09711003)。

摘　　要：新型冠状病毒感染仍然在全球流行。对于对新型冠状病毒疫苗有禁忌证的人群和无法对新型冠状病毒疫苗产生充足免疫反应的人群来说仍有大量预防用药需求未得到满足。本文围绕新型冠状病毒感染预防药物研究进展进行综述,介绍抗体类、小分子类预防药物的研究进展。作为目前唯一获批的具有暴露前预防作用的药物,evusheld对于奥密克戎的某些变种(XBB、XBB. 1.5、BQ. 1和BQ. 1.1)可能无效。面对新型冠状病毒的不断变异,新型冠状病毒感染预防药物研发仍然面临着巨大挑战。Corona virus disease 2019(COVID-19)is still prevalent worldwide.For individuals who contraindicated to or cannot produce adequate immune response to COVID-19 vaccine,there is still a large number of unmet demand for prophylaxis drugs.This article reviewed the research progress of prophylaxis drugs for COVID-19,including antibody drugs and small molecule drugs.Currently,Evusheld is the only approved drug with pre-exposure prophylaxis effect,however it may not be ef 2.The Third Clinical Medical College,Nanjing University of Chinese Medicine,Nanjing 210028,Chinafective for some variants of Omicron(XBB,XBB.1.5,BQ.1 and BQ.1.1).In order to cope with the constant variation of severe acute respiratory syndrome coronavirus 2,the research and development of prophylaxis drugs for COVID-19 still faces great challenges.

关 键 词：新型冠状病毒感染 预防药物 免疫功能低下人群 evusheld 

分 类 号：R978.7[医药卫生—药品]